Bone Marrow & Stem Cell Transplant

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.

Ruxolitinib shows sustained efficacy and safety in treating steroid-refractory chronic graft-vs-host disease, outperforming standard therapies over three years.

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and axatilimab in patients with chronic graft-vs-host disease.

Explore the complexities of chronic GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies.

A groundbreaking trial shows promising survival rates and low GVHD in patients receiving mismatched stem cell transplants, expanding treatment options for diverse populations.

A novel combination therapy shows high response rates in relapsed DLBCL, enhancing eligibility for autologous stem cell transplantation.

New trial data reveals cyclophosphamide plus cyclosporin significantly enhances GVHD prevention in stem cell transplant patients, offering hope for better outcomes.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after transplant.

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.

Panelists discuss how clinicians typically taper steroids slowly after starting second-line agents for chronic graft-vs-host disease (cGVHD).

Panelists discuss how most clinicians prefer ruxolitinib over ibrutinib as second-line therapy due to better tolerability

Panelists discuss how FDA-approved therapies such as ibrutinib, ruxolitinib, belumosudil, and axatilimab provide treatment options for steroid-refractory chronic graft-vs-host disease (cGVHD).

Panelists discuss how prophylaxis against opportunistic infections is essential for patients on immunosuppressive therapy for chronic graft-vs-host disease (cGVHD).

Panelists discuss how specialists balance controlling chronic graft-vs-host disease (cGVHD) symptoms while minimizing steroid exposure when patients fail initial therapy.

Panelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.

Panelists discuss how patient education and multidisciplinary involvement are critical for early detection of chronic graft-vs-host disease (cGVHD).

Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia, per phase 2 trial findings.

Amandeep Salhotra, MD, discusses data from the phase 3 Precision-T trial of Orca-T in patients with advanced hematologic malignancies.

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been accepted by the FDA.

With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with PTLD may resume.

Amandeep Salhotra, MD, discusses Orca-T and its evaluation in the phase 3 Precision-T trial in patients with advanced hematologic malignancies.

Panelists discuss how difficult-to-diagnose cases of chronic graft-vs-host disease (cGVHD) often include pulmonary involvement, gynecological manifestations, and neurological symptoms.